Is it safe to continue sitagliptin during a hospital admission for an acute illness?

Sitagliptin Should Generally Be Discontinued During Acute Illness Hospitalization

The standard recommendation is to discontinue oral diabetes medications, including sitagliptin, upon hospital admission for acute illness and transition to insulin-based therapy. 1

Primary Guideline Recommendations

The 2012 and 2022 Endocrine Society guidelines explicitly state to "discontinue oral diabetes drugs and non-insulin injectable diabetes medications upon hospital admission" 1, 2. This recommendation is based on several critical factors:

Why Discontinuation is Standard Practice

• Contraindications are common: A high percentage of acutely ill patients develop contraindications during hospitalization (sepsis, NPO status, IV contrast administration, renal failure, hemodynamic instability) 1

• Slow onset of action: Oral agents cannot allow rapid dose adjustment to meet the changing needs of acutely ill patients 3

• Limited utility with reduced oral intake: DPP-4 inhibitors like sitagliptin work primarily to reduce post-prandial glucose excursions and are "less useful in patients who are not eating or have reduced oral intake" 1

• Insulin is superior: Conversion to basal-bolus insulin therapy is both safe and efficacious, allowing for precise titration based on point-of-care glucose readings 1

The Exception: Emerging Evidence for Select Stable Patients

More recent 2017 guidelines acknowledge evolving evidence suggesting sitagliptin may be safe in highly selected hospitalized patients 3:

When Sitagliptin Might Be Considered

Only in patients who meet ALL of the following criteria:

• Clinically stable (not critically ill)
• Eating regular meals with adequate oral intake
• Mild to moderate hyperglycemia only
• No contraindications (normal renal function requiring dose adjustment: 50-100mg based on kidney function)
• Non-cardiac surgery patients
• Elderly patients where simplifying regimens reduces hypoglycemia risk

Supporting Evidence

A pilot randomized trial showed sitagliptin alone or combined with basal insulin resulted in "no significant differences in mean daily blood glucose, frequency of hypoglycemia, or number of treatment failures compared with a basal-bolus regimen" 3. Similar findings were replicated in a multicenter trial of 279 patients 4.

Critical Safety Concerns

Contraindications During Acute Illness

• Renal impairment: Requires dose adjustment; many acutely ill patients develop acute kidney injury
• NPO status or poor oral intake: Renders the medication ineffective
• Hemodynamic instability: Unpredictable absorption and metabolism
• Cardiac surgery patients: A 2021 RCT showed sitagliptin did NOT prevent perioperative hyperglycemia in CABG patients 5

Heart Failure Considerations

While sitagliptin can be used in patients with heart failure in outpatient settings 6, one retrospective study found an association with increased HF-related hospitalizations (adjusted OR 1.84) in patients with pre-existing heart failure 7. This warrants caution during acute admissions.

Practical Algorithm for Decision-Making

For most acutely ill patients:

1. Discontinue sitagliptin on admission
2. Initiate correctional insulin for glucose >140 mg/dL 2
3. Add scheduled basal insulin if ≥2 readings ≥180 mg/dL in 24 hours 2
4. Target glucose 100-180 mg/dL (non-critical care) 2, 8

For stable, eating patients with mild hyperglycemia:

1. May consider continuing sitagliptin IF:
   • Patient is clinically stable
   • Eating all meals
   • No renal impairment (adjust dose if eGFR <50)
   • No cardiac surgery planned
   • Glucose <200 mg/dL
2. Always have correctional insulin available
3. Monitor closely for deterioration requiring insulin transition

Common Pitfalls to Avoid

• Don't assume home medications should continue: Acute illness changes insulin sensitivity and creates new contraindications
• Don't use sitagliptin in NPO patients: It won't work effectively
• Don't delay insulin initiation: Waiting for oral agents to work can adversely affect outcomes 1
• Don't forget renal dosing: Sitagliptin requires adjustment for renal function

Discharge Planning

At discharge, patients with HbA1c <7.5-8% who were clinically stable can often be restarted on their prehospitalization oral regimen, including sitagliptin 3. Those with HbA1c >9% should be discharged on insulin-based regimens 3.